Clinical Trials Sponsored by Fondation ARCAD

Total 17710 results

GCS IHFB Cognacq-Jay
Fondation ARCAD

Active, not recruiting

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (TWICE-IRI)

Metastasis | Cancer Colorectal

France
Federation Francophone de Cancerologie Digestive
Fondation ARCAD

Recruiting

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA (KANALRAD)

Anal Cancer

France
GERCOR - Multidisciplinary Oncology Cooperative...
Fondation ARCAD

Recruiting

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC)

Neuroendocrine Carcinoma | Digestive Cancer

France
Ariad Pharmaceuticals

Terminated

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Chronic Myeloid Leukemia

United States, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, Slovakia, Spain, Sweden, Switz... and more
Ariad Pharmaceuticals
Takeda

Active, not recruiting

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)

ALK-positive Advanced NSCLC

Korea, Republic of, United States, Spain, Taiwan, Canada, Hong Kong, China, Sweden, Australia, Italy, Japan, Germany, Netherlands, France, Austria
Ariad Pharmaceuticals

Completed

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals

Completed

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)

Chronic Myeloid Leukemia | Ph+ Acute Lymphoblastic Leukemia

France, Belgium, Australia, Singapore, Germany, Spain, United Kingdom, Netherlands, Italy, Korea, Republic of, Sweden
IHU Strasbourg
IRCAD

Unknown

Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass

Morbid Obesity

France
Ariad Pharmaceuticals

No longer available

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Carcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced Malignancies

United States
Ariad Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Carcinoma, Non-Small-Cell Lung | Lymphoma, Large-Cell, Anaplastic
Ariad Pharmaceuticals

Completed

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Chronic Myelogenous Leukemia | Hematologic Malignancies

United States
ARCA Biopharma, Inc.

Completed

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

Thrombosis | Venous Thrombosis | Catheter Occlusion

United States
ARCA Biopharma, Inc.

Completed

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters

Thrombosis | Venous Thrombosis

United States
Ariad Pharmaceuticals

Completed

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Japan
Ariad Pharmaceuticals

Terminated

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (OPTIC-2L)

Chronic Phase Chronic Myeloid Leukemia

Belgium
Ariad Pharmaceuticals

Completed

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

Carcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced Malignancies

United States, Canada, Germany, Spain, Taiwan, Korea, Republic of, Switzerland, Hong Kong, Singapore, Italy, Sweden, United Kingdom, France, Netherlands, Denmark, Australia, Norway, Austria, Luxembourg
Ariad Pharmaceuticals

Completed

A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

GIST

United States
Ariad Pharmaceuticals

Approved for marketing

Expanded Access Program of Ponatinib

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

United States
ARCA Biopharma, Inc.

Unknown

Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery (SNAP-CABG-OFF)

Heart Disease
ARCA Biopharma, Inc.

Terminated

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

Arterial Occlusive Diseases

United States
ARCA Biopharma, Inc.
Medtronic

Completed

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (GENETIC-AF)

Current or Recent History of Atrial Fibrillation

United States, Canada, Hungary, Netherlands, Poland, Serbia
ARCA Biopharma, Inc.

Completed

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

Catheters, Indwelling

United States
ARCA Biopharma, Inc.

Suspended

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Colon Cancer

United States
ARCA Biopharma, Inc.

Terminated

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Acute Ischemic Stroke

United States, Canada
ARCA Biopharma, Inc.

Completed

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

Arterial Occlusive Diseases

United States
University of Colorado, Denver
Ariad Pharmaceuticals

Completed

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Adenocarcinoma of the Lung

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Sarcoma
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Solid Tumor
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Non-Small Cell Lung Cancer
ARCA Biopharma, Inc.
Health Decisions

Completed

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

Arterial Occlusive Diseases | Thrombosis | Peripheral Vascular Diseases

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Advanced Cancers
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Prostate Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Sarcoma | Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

Hepatic Insufficiency | Healthy Volunteers
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Endometrial Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (SUCCEED)

Metastatic Soft-Tissue Sarcomas | Metastatic Bone Sarcomas
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Sarcoma, Soft Tissue | Osteosarcoma | Leiomyosarcoma | Liposarcoma | Metastases
ANRS, Emerging Infectious Diseases
UMR 1252 SESSTIM; ARCAD Santé PLUS; SEREFO

Unknown

ANRS 12392 Sanu Gundo (SANU GUNDO)

HIV Infections

Mali
University of Texas at Austin
Arcade Therapeutics

Not yet recruiting

Confirmatory Efficacy Trial of Attention Bias Modification for Depression

Depression

United States
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Terminated

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Leukemia

United States
Ariad Pharmaceuticals
United BioSource, LLC

Terminated

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (OMNI)

Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Prostate Cancer

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancies | Myeloid Metaplasia

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Glioblastoma | Malignant Glioma | Gliosarcoma

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Neoplasms
OHSU Knight Cancer Institute
Ariad Pharmaceuticals

No longer available

Compassionate Use Ponatinib

Chronic Myeloid Leukemia | Philadelphia Chromosome Positive (Ph+) Leukemias

United States

Clinical Trials Sponsored by Fondation ARCAD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations